Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A German, non-Interventional study of NEPA (fixed dose Netupitant/Palonosetron) for the prevention of chemotherapy induced nausea and vomiting

X
Trial Profile

A German, non-Interventional study of NEPA (fixed dose Netupitant/Palonosetron) for the prevention of chemotherapy induced nausea and vomiting

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Jan 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Netupitant/palonosetron (Primary)
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Acronyms AkyPRO
  • Most Recent Events

    • 11 Dec 2020 Results of post-hoc analysis assessing quality of life data and effectiveness of NEPA in the subgroup of Breast Cancer patients in two age groups > and <60 years, presented at the 43rd Annual San Antonio Breast Cancer Symposium.
    • 08 Dec 2020 Status changed from active, no longer recruiting to completed.
    • 08 Dec 2020 Results of quality of life presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top